© 2021 Jnana Therapeutics - All rights reserved.
– Company co-founder and scientific leader will drive future growth of chemoproteomic product engine and pipeline programs – Boston, Mass., November 2, 2021 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target well-validated but hard-to-drug targets, today announced the promotion of Joel Barrish, Ph.D., a co-founder of the company, to President and Chief […]
– Funds progression of lead program, an oral approach to treating phenylketonuria (PKU), into the clinic – – Supports expanded application of chemoproteomic RAPID platform for small-molecule discovery for hard-to-drug targets – Boston, Mass., August, 18, 2021 – Jnana Therapeutics, a biotechnology company utilizing its next generation chemoproteomic platform to target SLC transporters and other […]
Company appoints Nick Pullen, PhD, as Senior VP, Head of Biology and Brian Danieli as VP, Head of Finance & Operations Boston, Mass. – February 3, 2021 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced that it has expanded its leadership team […]
Veteran leaders bring deep scientific and clinical expertise as Jnana advances its pipeline toward the clinic Boston, Mass. – January 6, 2021 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of two experienced scientific and clinical leaders to the company’s […]
Jnana to receive $40 million upfront and is eligible to receive milestone payments with potential for future payments exceeding $1 billion Boston, MA – July 21, 2020 – Jnana Therapeutics today announced a strategic, multi-target collaboration and license agreement with Roche (SIX: RO, ROG; OTCQX: RHHBY) for the discovery of small molecule drugs directed at […]
Boston, Mass., October 1, 2019 – Jnana Therapeutics, a biotechnology company targeting the solute carrier (SLC) family of metabolite transporters to treat underserved diseases, today announced the appointment of Caroline Stark Beer as its chief business officer. Ms. Stark Beer joins Jnana after over a decade at Alnylam Pharmaceuticals, where she served in a variety of […]
Boston, Mass., April 5, 2019 – Jnana Therapeutics today announced the appointment of Donald Nicholson, Ph.D., an accomplished scientist and executive, as chair of its Board of Directors. Don most recently served as chief executive officer of Nimbus Therapeutics. “I am thrilled to welcome Don as chair of our Board of Directors. Don’s experience and […]
Stuart Schreiber, Ph.D. and Brian Cali, Ph.D. appointed to Board Inaugural SAB comprises renowned leaders in the investigation of disease biology and applications to drug discovery and development Boston, Mass. – Dec. 20, 2018 – Jnana Therapeutics today announced the appointment of two new members to its Board of Directors: Stuart Schreiber, Ph.D., a co-founder […]
Boston Mass. – Nov. 6, 2018 – Jnana Therapeutics today announced that Joanne Kotz, Ph.D., a company co-founder, has been named Chief Executive Officer. Dr. Kotz has served as Jnana’s president since December 2017. “Joanne has demonstrated exceptional leadership in guiding the company through its early stages of growth, and we believe she is the […]
Partnership Leverages Neurocrine’s Expertise in Neuroscience and Jnana’s Proprietary Drug Discovery Platform Targeting the Solute Carrier Family of Transporters SAN DIEGO and BOSTON, Oct. 9, 2018 – Neurocrine Biosciences, Inc. (NASDAQ: NBIX) and Jnana Therapeutics Inc. today announced that they have entered into a research collaboration aimed at discovering novel small molecule therapeutics for multiple […]
Pharmaceutical Business Review
Scripps Research, April 2020
Chemical and Engineering News, October 2018
2020 Fall ACS Meeting - Joel Barrish (CSO)
By Joanne Kotz (CEO) and Joel Barrish (CSO)
This links to an external website. Merus is not responsible for any third party content.